Webinar image
Webinar image
  • Blog Post

Webinar: New Medication Options in Behavioral Health

Oct 8th, 2021

Behavioral Health Drug Updates

This year the Federal Drug Administration’s Center for Drug Evaluation and Research (CDER) approved a number of new drug therapies to treat behavioral health conditions, including new drugs for treating attention-deficit/hyperactivity disorder (ADHD), schizophrenia, and more. What do behavioral health care providers need to know about these new medications?

Genoa Healthcare’s Vice President of Pharmacy Solutions Abbie Vogler, PharmD, recently hosted a webinar in which she addressed new behavioral drugs and their unique attributes. To learn more, watch the webinar, which:

  • Explores new behavioral health drugs approved in 2021
  • Reviews 2020 drug approvals and the recent pace of FDA approvals
  • Looks ahead to coming drug trends
  • Provides an update on COVID-19 vaccine developments

You can also read highlights from this webinar here and check out our FAQ here.

To learn more about how Genoa can help you and those you serve, contact us today.

Recent Posts

  • Blog Post
Partnering with ACT teams to make an even bigger impact

Genoa Healthcare® pharmacist Julie R. has seen firsthand the impact that severe and persistent mental illness can have on a person. For one of her consumers living with schizophrenia, the...

  • Blog Post
  • Webinar
For consumers living with Tardive Dyskinesia, Genoa Healthcare’s Clinical Assistance Program offers personalized support

Tardive Dyskinesia – a neurological disorder linked to prolonged use of antipsychotic medications – impacts over 600,000 individuals each year. Did you know that 50% of consumers taking TD medication...

  • Blog Post
A foundation to build on: 3 ways an engaged pharmacy partner helps you deliver whole-person health

A recent survey found that nearly 60% of behavioral health, primary care and complex care providers reported that their organization currently offered or had plans to begin offering integrated care...

  • Clinical Insights
  • Webinar
Understanding Tardive Dyskinesia: What you need to know

Tardive Dyskinesia (TD) – a neurological disorder associated with prolonged use of antipsychotic medications – affects over 600,000 people annually. Wondering what this means for the people you serve? Genoa...